BioLight Life Sciences Ltd. engages in the investment, development, management, and commercialization of products in the fields of advanced medical devices, pharmaceuticals, diagnostics, and digital medicine in Israel. The company offers TeaRx, a diagnostic platform intended for point-of-care testing of ophthalmic pathologies through multi-parameter composition analysis of the tear fluid; TeaRx Dry Eye Syndrome; and Ocuvia, a front-to-back ocular treatment that includes ocudrip and ocugrid. It also provides Eye-D technology which treats glaucoma by the insertion of a sub-conjunctival implant; and Ocular D, a product for treating dryness in the eye with integrated vitamin D. In addition, the company engages in the development of drugs for treating eye diseases using a technological platform that enhances the transmission of active substances based on nanostructures. The company was formerly known as Bio Light Israeli Life Sciences Investments Ltd. and changed its name to BioLight Life Sciences Ltd. in February 2016. BioLight Life Sciences Ltd. was incorporated in 2005 and is based in Ramat Gan, Israel.